Aidea Pharma(688488)2024-04-25 10:36Financial Performance - The company's operating revenue for Q1 2024 was ¥92,893,957, representing a decrease of 17.52% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥13,606,889.35, indicating a significant loss[3]. - Total operating revenue for Q1 2024 was ¥92,893,957, a decrease of 17.6% compared to ¥112,621,308.59 in Q1 2023[19]. - Net loss for Q1 2024 was ¥13,606,889.35, compared to a net profit of ¥486,169.74 in Q1 2023, indicating a significant decline in profitability[20]. - Basic and diluted earnings per share for Q1 2024 were both -¥0.03, compared to ¥0.0012 in Q1 2023[21]. Research and Development - Research and development expenses totaled ¥20,314,126.77, an increase of 31.16% year-over-year, accounting for 21.87% of operating revenue, up by 8.12 percentage points[3][6]. - The company continues to focus on new product development, which has led to increased R&D investments despite the decline in revenue[6]. - Research and development expenses surged to ¥17,748,750.48 in Q1 2024, up 80.5% from ¥9,828,619.27 in Q1 2023[20]. Assets and Liabilities - The total assets at the end of Q1 2024 were ¥1,752,515,683.14, a slight increase of 0.34% from the end of the previous year[4]. - The company's total liabilities increased to ¥569.06 million from ¥491.57 million, representing a rise of approximately 16%[16]. - The company's total liabilities amounted to ¥638,693,728.75 in Q1 2024, an increase from ¥621,027,157.38 in Q1 2023[17]. - The total equity attributable to shareholders decreased to ¥1,113,821,954.39 in Q1 2024 from ¥1,125,538,212.91 in Q1 2023, a decline of 1.0%[17]. Cash Flow - The net cash flow from operating activities was -¥70,322,344.42, indicating a negative cash flow situation[3]. - Cash inflow from operating activities was ¥72,666,436.67 in Q1 2024, compared to ¥67,546,626.96 in Q1 2023, reflecting a growth of 7.3%[22]. - The net cash flow from operating activities was -56.42 million in the previous year, indicating a decline in operational cash generation[23]. - Cash inflow from investment activities totaled 423.24 million year-over-year, with a net cash flow from investment activities of 101.65 million previously[23]. - Cash inflow from financing activities was 52.40 million in the prior year, resulting in a net cash flow from financing activities of 17.89 million[23]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 8,237[8]. - The largest shareholder, Guangzhou Weimei Investment Co., Ltd., holds 22.46% of the shares, totaling 94,500,000 shares[8]. Market and Product Development - In Q1 2024, the sales revenue of HIV new drugs reached RMB 35.71 million, representing a year-on-year growth of 76.52%[10]. - The company has established a commercial operation system for HIV new drugs, focusing on patients with lipid and weight issues who demand a high quality of life[10]. - The company is actively advancing its overseas market strategy, which is expected to create new growth points for its HIV innovative drug business[11]. - The clinical trial for the drug Ainomi Tablets has shown positive results in its 96-week Phase III study[11]. - The clinical trial results for the drug Anomiravir (复邦德®) showed a viral suppression rate of 96.6% (<50 copies/mL) after 96 weeks, outperforming historical data of similar imported products[12]. - The real-world study of the Anovelin regimen demonstrated comparable efficacy to the Efavirenz regimen, with a significant reduction in adverse effects related to lipid metabolism and central nervous system issues[13]. - The Phase I clinical trial of the new integrase inhibitor ACC017 has shown good safety across all dosage groups, with no severe adverse events reported[13]. - The company plans to present its Phase III clinical research results at the upcoming AIDS 2024 conference in Germany, enhancing its international academic presence[13]. - The company aims to leverage academic publications to promote its core products on the international stage, indicating a strategic focus on global market expansion[13]. Other Financial Metrics - The company reported non-recurring gains of ¥3,772,815.54 for the period, primarily from government subsidies and financial asset disposals[6]. - The company's cash and cash equivalents increased to ¥256.84 million from ¥225.36 million at the end of 2023, reflecting a growth of approximately 14%[15]. - The accounts receivable rose to ¥210.49 million, up from ¥182.42 million, indicating a growth of about 15%[15]. - The long-term equity investments increased to ¥97.88 million from ¥91.87 million, showing a growth of about 6.5%[16]. - The company reported an investment income of ¥7,573,963.00 in Q1 2024, up from ¥4,079,688.68 in Q1 2023, marking an increase of 85.1%[20]. - Deferred income tax liabilities rose to ¥6,474,799.56 in Q1 2024 from ¥6,278,458.48 in Q1 2023, an increase of 3.1%[17]. - The company paid 35.41 million year-over-year, reflecting a rise in employee compensation[23]. - Tax payments increased to 2.23 million, indicating a higher tax burden on the company[23]. - Cash outflow for other operating activities was 32.02 million, showing a minor reduction in operational expenses[23]. - The company reported cash outflow for investment activities of 321.59 million, indicating a reduction in capital expenditures[23]. - The impact of exchange rate changes on cash and cash equivalents was a positive 271,524 in the previous year[23]. - The company did not adopt new accounting standards for the current reporting period, maintaining consistency in financial reporting[24].